Przeglądaj wg Słowo kluczowe "POSEIDON"

Teraz wyświetlane 1 - 2 z 2
  • Miniatura
    Pozycja
    Analysis of the day 3 transfer strategy for POSEIDON patients
    (SBRA - Associação Brasileira de Reprodução Assistida, 2025-07-30) Wyroba, Jakub; Kochan, Joanna
    Abstract: „Objective: The aim of the study was to analyze the effectiveness of the day 3 ET strategy, and the morphology of the transferred embryos, in patients from POSEIDON and non-POSEIDON groups. Methods: 600 cycles of patients meeting the POSEIDON criteria and 600 non-POSEIDON cycles were analyzed to determine the proportion of cycles with an ET on days 3 or 5, or FET. Then we reviewed 330 day 3 ETs to compared the developmental stage, morphology, zona pellucida thickness and implantation potential of embryos transferred on day 3 from POSEIDON and non-POSEIDON patients. Results: Most cycles of POSEIDON patients end with ET on day 3 (42%) or without transfer (37%). In contrast, most cycle of non-POSEIDON patients end with FET (44%) and just 9% is canceled. The lowest percentage of embryos at the morula stage was recorded in POSEIDON groups III (10%) and IV (9%). The average number of cells in embryos was comparable in all groups. The largest percentage of top-quality embryos (grade A) were in POSEIDON group I (47%) .The highest implantation potential were observed in the non-POSEIDON group <35Y (28%), and in POSEIDON groups I (28%) and III (26%). The highest incidence of miscarriage was recorded in all POSEIDON and non-POSEIDON groups that included patients who were ≥35 years of age. Conclusions: The day 3 ET strategy still seems optimal for POSEIDON patients. The prognosis depends on which Poseidon group the patient is in. The best prognosis is for group I and the worst for group IV.”(…)
  • Miniatura
    Pozycja
    PGT-A in POSEIDON Patients - perspectives and limitations
    (SBRA - Associação Brasileira de Reprodução Assistida, 2025-12-10) Wyroba, Jakub; Barszcz, Maria; Fajt, Iwona; Kochan, Joanna
    Abstract: „Objective: The aim of this study was to determine the likelihood of being able to perform PGT-A, and its results, in each POSEIDON group compared to their age-matched non-POSEIDON group. Methods: This was a retrospective study of 4 groups of POSEIDON patients (n=824) who underwent intracytoplasmic sperm injection (ICSI) The controls were non-POSEIDON patients in two age groups (<35 and ≥35 years old; n=360). Results: The non-POSEIDON <35Y group had the highest number of embryos at the blastocyst stage that could be used for PGT-A (5.1±2/cycle), and the POSEIDON IV group had the fewest (0.6±0.3/cycle). Significantly fewer blastocysts were PGT-A tested in the groups with no indications for PGT-A (i.e. POSEIDON I (26%) and III (28%) and non-POSEIDON <35Y (39%)), compared to the groups with indications (i.e. POSEIDON II (69%), and IV (67%) and non POSEIDON ≥35Y (72%)). The euploidy rate was similar between groups without PGT-A indications (59%-64%) and between groups with indications (35-41%), but was significantly lower in groups with indications (p<0.001). Conclusions: POSEIDON patients are as willing to undergo PGT-A testing as non-POSEIDON patients, despite the poor prognosis. However, the final PGT-A result is very low compared to that in non-POSEIDON patients of the same age. Failure is usually caused by the inability to perform the blastocyst biopsy due to a lack of oocytes or blastocyst-stage embryos, and to a low rate of euploidy in groups ≥35Y.”(…)